Interferon alpha/beta receptor 1 Antibody (YA3833)
(Synonyms: AVP; IFRC; IFNAR; IFNBR; IFN-alpha-REC)Based on 1 Customer Validation
Interferon alpha/beta receptor 1 Antibody (YA3833) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Interferon alpha/beta receptor 1.
-
Host:
Mouse
-
Isotype:
IgG1
-
Application:
WB, IHC-P, FC, ELISA
-
Reactivity :
Human, Mouse
-
Formulation:
Supplied in PBS with 0.05% sodium azide
-
Conjugation:
Non-conjugated
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
Applications
| Application |
WB
WB: Western Blot
|
IHC-P
IHC-P: Immunohistochemistry-Paraffin
|
FC
FC: Flow Cytometry
|
ELISA
ELISA: Enzyme Linked Immunosorbent Assay
|
|---|---|---|---|---|
| Dilution Ratio | 1:500-1:2000 | 1:200-1:1000 | 1:200-1:400 | 1:10000 |
Product Details
Interferon alpha/beta receptor 1 Antibody (YA3833) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Interferon alpha/beta receptor 1.
-
Host Mouse
-
Clonality Monoclonal
-
Species ReactivityHuman, Mouse
-
Observed Molecular WeightObserved band size: 110-130 kDa
Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
-
Calculated Molecular Weight Predicted band size: 64 kDa
Purified recombinant fragment of human IFNAR1 (AA: 28-156) expressed in E. Coli.
affinity purified.
Non-conjugated
Unmodified
IgG1
Product Properties
-
Appearance
Liquid
-
Formulation
Supplied in PBS with 0.05% sodium azide
-
Concentration
Batch-dependent, Please check the COA for the concentration of each lot. Check Lot Concentration
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Background
-
Function
Interferon alpha/beta receptor 1 is a Together with IFNAR2, forms the heterodimeric receptor for type I interferons (including interferons alpha, beta, epsilon, omega and kappa). Type I interferon binding activates the JAK-STAT signaling cascade, resulting in transcriptional activation or repression of interferon-regulated genes that encode the effectors of the interferon response. Mechanistically, type I interferon-binding brings the IFNAR1 and IFNAR2 subunits into close proximity with one another, driving their associated Janus kinases (JAKs) (TYK2 bound to IFNAR1 and JAK1 bound to IFNAR2) to cross-phosphorylate one another. The activated kinases phosphorylate specific tyrosine residues on the intracellular domains of IFNAR1 and IFNAR2, forming docking sites for the STAT transcription factors. STAT proteins are then phosphorylated by the JAKs, promoting their translocation into the nucleus to regulate expression of interferon-regulated genes. Can also act independently of IFNAR2: form an active IFNB1 receptor by itself and activate a signaling cascade that does not involve activation of the JAK-STAT pathway[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15].
-
Subcellular Localization
Cell membrane; Single-pass type I membrane protein; Late endosome; Lysosome
-
Expression
Tissue_specificity:Interferon receptors are present in all tissues, even on the surface of most interferon-resistant cells. Isomers 1, 2, and 3 are expressed in the interferon-α-sensitive myeloma cell line U266B1. Isomers 2 and 3 are expressed in the interferon-α-resistant myeloma cell line U266R. Isomer 1 is not expressed in the interferon-α-resistant myeloma cell line U266R. -
Isoforms & Post-Translational Modification
P17181 has 4 isomers: P17181-1: 63525 Da (predicted); P17181-2: 49547 Da (predicted); P17181-3: 56718 Da (predicted); P17181-4: 56046 Da (predicted).
Ubiquitinated, leading to its internalization and degradation (PubMed:14532120, PubMed:15337770). Polyubiquitinated via 'Lys-48'-linked and 'Lys-63'-linked ubiquitin chains, leading to receptor internalization and lysosomal degradation (PubMed:18056411). The 'Lys-63'-linked ubiquitin chains are cleaved off by the BRISC complex (PubMed:24075985);Phosphorylated on tyrosine residues in response to interferon-binding: phosphorylation by TYK2 tyrosine kinase creates docking sites for STAT proteins (PubMed:10049744, PubMed:7526154). Phosphorylated on serine residues in response to interferon binding; this promotes interaction with FBXW11 and ubiquitination (PubMed:14532120, PubMed:15337770, PubMed:24075985);Palmitoylation at Cys-463 is required for the activation of STAT1 and STAT2 -
Subunit
Heterodimer with IFNAR2; forming the receptor for type I interferon (PubMed:10049744, PubMed:21854986, PubMed:7665574). Interacts with TYK2 (PubMed:15337770, PubMed:24704786, PubMed:7526154). Interacts with STAT1 and STAT2; the interaction requires its phosphorylation at Tyr-466 (PubMed:9121453). Interacts (serine-phosphorylated form) with FBXW11, the substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex (PubMed:14532120, PubMed:15337770, PubMed:18056411). Interacts with SHMT2; this promotes interaction with ABRAXAS2 and the BRISC complex (PubMed:24075985). Interacts with TRIM10; this interaction prevents association between IFNAR1 and TYK2 (PubMed:33811647)
-
SwissProt ID
-
Synonyms
AVP; IFRC; IFNAR; IFNBR; IFN-alpha-REC
Documentation
-
Data Sheet (235 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
User Guide for Antibodies (1077 KB)
Powered by Bioz
